The Canadian CF Gene Modifier Study (CGMS) was approved by the Research Ethics Board of the Hospital for Sick Children (# 0020020214 from 2012 to 2019 and #1000065760 from 2019-present) and all participating sub-sites. Written informed consent was obtained from all participants or parents/guardians/substitute decision makers prior to inclusion in the study. The CGMS is also approved by the Research Ethics Board of the Hospital for Sick Children for the usage of public and external data. The US PROSPECT study provides data from a clinical trial registered at https://clinicaltrial.gov, identifier NCT02477319, and we obtained these data through application to the US CFF at https://www.cff.org/researchers/cf-foundation-biorepository.
Do you have any questions about this protocol?
Post your question to gather feedback from the community. We will also invite the authors of this article to respond.